<DOC>
	<DOCNO>NCT02486445</DOCNO>
	<brief_summary>This prospective outcome study design ass safety rivaroxaban pre-diagnosis phase DVT .</brief_summary>
	<brief_title>Rivaroxaban Scheduled Work-up DVT - The Ri-Schedule Study</brief_title>
	<detailed_description>This prospective outcome study design ass safety rivaroxaban pre-diagnosis phase DVT . International guideline suggest use low molecular weight heparin ( LMWH ) diagnostic process expect delay 4 hour . Rivaroxaban new DOAC clinical trial proven non-inferior LMWH warfarin treatment DVT add benefit cause less major bleeding . Because rapid onset action oral administration , rivaroxaban could use instead LMWH pre-diagnosis phase pending result diagnostic test . However , safety propose indication proven adopt clinical practice . This study aim determine safety feasibility pre-diagnostic treatment rivaroxaban . The primary outcome study `` safety '' composite endpoint serious bleeding encounter within 48 hour administration rivaroxaban .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Consecutive outpatient refer ER suspect DVT 18 year age Signed informed consent 1 refuse consent Patients criterion eligible schedule workup : 1 . Duration diagnostic workup expect last &lt; 2 hour 2 . Presence active cancer receive chemotherapy cancer 3 . Suspicion coexist clinical PE 4 . Suspicion active bleeding ( gastrointestinal bleeding muscle hematoma ) 5 . Signs threaten circulation intractable pain low extremity may consider candidate thrombolytic treatment 6 . Physician consider safe discharge patient 7 . Presence logistic factor may hinder schedule workup 8 . Presence comorbid condition require hospital admission 9 . Patient prefers discharge diagnosis complete 10 . Glomerular Filtration Rate &lt; 45 ml/min 11 . Presence contraindication rivaroxaban include ; Lesion condition , consider significant risk major bleed e.g current recent gastrointestinal ulceration , presence malignant neoplasms high risk bleeding , recent brain spinal injury , recent brain , spinal ophthalmic surgery , recent intracranial haemorrhage , know suspected oesophageal varix , arteriovenous malformation , vascular aneurysm major intraspinal intracerebral vascular abnormality Concomitant treatment anticoagulant e.g . unfractionated heparin ( UFH ) , low molecular weight heparin ( enoxaparin , dalteparin , etc . ) , heparin derivative ( fondaparinux , etc . ) , oral anticoagulant ( warfarin , dabigatran etexilate , apixaban etc . ) Hepatic disease associate coagulopathy clinically relevant bleeding risk include cirrhotic patient Child Pugh B C. Pregnancy/positive pregnancy test breastfeeding ( see section 4.6 ) 11 . Hb &lt; 10 g/dl platelet count &lt; 100x 109/l 12 . Presence drug interaction rivaroxaban include concomitant systemic treatment azoleantimycotics ( ketoconazole , itraconazole , voriconazole posaconazole ) HIV protease inhibitor ( e.g . ritonavir ) , acetylsalicylic acid dose high 160 mg platelet aggregation inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Deep venous thrombosis</keyword>
	<keyword>Rivaroxaban</keyword>
</DOC>